leukotriene-b4 and Urinary-Bladder-Neoplasms

Aggressive bladder cancer is a major cause of morbidity and mortality. Despite the fact that metastatic disease results in death in the majority of bladder cancer cases, the molecular events regulating the invasive phenotype of aggressive bladder cancer are not well understood. In this study, immunohistochemical examination showed that the leukotriene B(4) receptor BLT2 is overexpressed in advanced malignant bladder cancers (human transitional cell carcinomas) in proportion to advancing stages, with high prognostic significance (p<0.001). Blockade of BLT2 with the specific antagonist LY255283 or siRNA knockdown significantly suppressed the invasiveness of highly aggressive 253J-BV bladder cancer cells. Moreover, our results demonstrated that BLT2 mediates invasiveness through a signaling pathway dependent on NAD(P)H oxidase (Nox) 1- and Nox4-induced generation of reactive oxygen species (ROS) and subsequent NF-kappaB stimulation. Metastasis of 253J-BV cells in mice was also dramatically suppressed by inhibition of BLT2 or its signaling. These findings suggest that a BLT2-Nox-ROS-NF-kappaB cascade plays a critical role in bladder cancer invasion and metastasis.

Topics: Animals; Carcinoma; Cell Line, Tumor; Humans; Leukotriene B4; Lung Neoplasms; Mice; Mice, Nude; NADPH Oxidase 1; NADPH Oxidase 4; NADPH Oxidases; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm Transplantation; NF-kappa B; Prognosis; Reactive Oxygen Species; Receptors, Leukotriene B4; RNA, Small Interfering; Signal Transduction; Tetrazoles; Transcriptional Activation; Urinary Bladder Neoplasms